Why the CogState (ASX:CGS) share price is rocketing 36% higher today

The CogState Limited (ASX:CGS) share price is rocketing higher on Monday after announcing a major agreement with Japan’s Eisai…
The post Why the CogState (ASX:CGS) share price is rocketing 36% higher today appeared first on Motley Fool Australia. –

Investor riding a rocket blasting off over a share price chart

The CogState Limited (ASX: CGS) share price has been an exceptionally strong performer on Monday.

At the time of writing, the neuroscience technology company’s shares are up a massive 36% to a 52-week high of $1.08.

Why is the CogState share price rocketing higher?

Investors have been buying the company’s shares this morning following the announcement of an agreement with Japanese pharmaceutical company, Eisai.

According to the release, the agreement will see Eisai exclusively distribute Cogstate digital cognitive assessment technologies in healthcare and other markets world-wide.

The agreement excludes clinical trials, where Cogstate will continue to market its offering independently.

What are the terms of the agreement?

The release explains that Eisai will provide an upfront payment to Cogstate of US$15million, which is payable within 45 days.

The pharmaceutical company will also pay Cogstate a royalty on sales. This will be determined by a range of factors including the retail market price of Cogstate technology in all regions or calculated on a per user basis.

Eisai will also fund necessary product development activities to further tailor Cogstate solutions for each territory and use case and be responsible for all commercial activities in respect of the sale and marketing of the technology in all territories.

The agreement has an initial term of ten years for each country, from its first commercial product sale on a country by country basis. Eisai has agreed to make commercially reasonable efforts to make its first sales in the US within 1 year, the EU with 3 years, and China with 4 years.

Furthermore, the agreement provides for cumulative royalties of at least US$30 million over the term of the license, unless terminated earlier.

The minimum royalties will be no less than US$10 million for the period of years one to five and then no less than US$20 million for the period of years six to ten.

What is CogState’s technology?

The company’s technology optimises brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.

It provides rapid, reliable, and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions. These can replace costly and error-prone paper assessments with real-time data capture.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the CogState (ASX:CGS) share price is rocketing 36% higher today appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!